Cefepime Mylan

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base; Cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base

Disponible desde:

Viatris Limited

Designación común internacional (DCI):

Cefepime dihydrochloride monohydrate 1.1518 g (equivalent to 1 g cefepime free base)

Dosis:

1 g

formulario farmacéutico:

Powder for injection

Composición:

Active: Cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base Excipient: Arginine Active: Cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base Excipient: Arginine

Unidades en paquete:

Vial, glass, single dose, Type I clear glass vial with grey bromo butyl rubber stopper, 1 g

clase:

Prescription

tipo de receta:

Prescription

Fabricado por:

Fresenius Kabi Anti-Infectives S.r.l.

indicaciones terapéuticas:

CEFEPIME Mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · Lower respiratory tract infections, including pneumonia and bronchitis. · Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · Skin and skin structure infections. · Septicaemia. · Intra-abdominal infections, including peritonitis and biliary tract infections. · Empiric treatment of febrile neutropenia.

Resumen del producto:

Package - Contents - Shelf Life: Vial, glass, single dose, Type I clear glass vial with grey bromo butyl rubber stopper and flip off aluminium seal - 1 g - 2 years from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at or below 25°C protect from light 168 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light

Fecha de autorización:

2009-06-17